Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000261712 | SCV000430680 | benign | Cystinuria | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. |
Invitae | RCV000261712 | SCV001733481 | benign | Cystinuria | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001672579 | SCV001883804 | benign | not provided | 2020-01-18 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000261712 | SCV002057060 | benign | Cystinuria | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Biotechnology Lab, |
RCV000261712 | SCV004037440 | pathogenic | Cystinuria | 2023-02-10 | criteria provided, single submitter | research | A molecular and computational study performed on the Pakistani population reported this missense variant (M618I) in the SLC3A1 gene, as a pathogenic variant, by using the technique of Next-generation sequencing. The variant was potentially involved in causing Cystinuria by altering the structural and functional effect of the rBAT protein coded by the SLC3A1 gene. The variant was confirmed by ARMS-PCR at the population level (Zafar & Awais, 2023). |